Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting
October 20 2017 - 8:00AM
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the
presentation of a poster addressing results with the company’s
pan-caspase inhibitor IDN-7314 in a mouse model of primary
sclerosing cholangitis (PSC) at The Liver Meeting®, the annual
meeting of the American Association for the Study of Liver Diseases
(AASLD) in Washington, DC, October 20-24, 2017.
Poster #287, “Cholestasis induced intestinal dysbiosis augments
liver disease in a murine model of primary sclerosing cholangitis,”
will be presented by lead author Lijun Liao, Researcher in the
Department of Internal Medicine III, University Hospital RWTH
Aachen, Aachen, Germany.
The poster will be displayed in the Poster and Exhibit Hall on
Level 2 of the Walter E. Washington Convention Center in Poster
Session I on Friday, October 20, from 8:00 a.m. to 5:30 p.m. EDT,
with authors available for discussion at the posters from 12:00
p.m. to 1:30 p.m. EDT.
IDN-7314 is an orally active pan-caspase protease inhibitor
designed to reduce the activity of enzymes that mediate
inflammation and cell death (or apoptosis), which has demonstrated
reduction of relevant biomarkers in two preclinical models of PSC.
The Mdr2-/- mouse model is considered the current benchmark
nonclinical model of PSC. IDN-7314 also reduced biochemical markers
in a new acute preclinical model of PSC. These results suggest the
involvement of caspases in the progression of PSC.
About Conatus PharmaceuticalsConatus is a
biotechnology company focused on the development and
commercialization of novel medicines to treat liver disease. In
collaboration with Novartis, Conatus is developing its lead
compound, emricasan, for the treatment of patients with chronic
liver disease. Emricasan is a first-in-class, orally active
pan-caspase inhibitor designed to reduce the activity of enzymes
that mediate inflammation and apoptosis. Conatus believes that by
reducing the activity of these enzymes, caspase inhibitors have the
potential to interrupt the progression of a variety of diseases.
For additional information, please visit www.conatuspharma.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. All
statements other than statements of historical facts contained in
this press release are forward-looking statements, including
statements regarding caspase inhibitors' potential to interrupt the
progression of a variety of diseases. In some cases, you can
identify forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplates,” “believes,” “estimates,”
“predicts,” “potential” or “continue” or the negative of these
terms or other similar expressions. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions,
including those risks described in the company’s prior press
releases and in the periodic reports it files with the Securities
and Exchange Commission. The events and circumstances
reflected in the company’s forward-looking statements may not be
achieved or occur and actual results could differ materially from
those projected in the forward-looking statements. Except as
required by applicable law, the company does not plan to publicly
update or revise any forward-looking statements contained herein,
whether as a result of any new information, future events, changed
circumstances or otherwise.
CONTACT: Alan EngbringConatus Pharmaceuticals
Inc.(858) 376-2637aengbring@conatuspharma.com
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conatus Pharmaceuticals (NASDAQ:CNAT)
Historical Stock Chart
From Apr 2023 to Apr 2024